Brief: Dr. Lal Pathlabs Says Adverse Impact Of Lockdown On Co's Revenue Seen Until Q2 FY21
02/06/2020 10:54
June 2 (Reuters) - Dr. Lal PathLabs Ltd DLPA.NS :
* ADVERSE IMPACT OF LOCKDOWNS/RESTRICTIONS ON CO'S REVENUE
EXPECTED TO CONTINUE UNTIL Q2 FY21
* REVENUE FROM COVID-19 TESTING ONLY CONTRIBUTING TO
RECOVERY OF
FIXED AND VARIABLE COSTS INCURRED BY CO FOR SUCH TESTS
* REVENUE FROM COVID-19 TESTING NOT EXPECTED TO BE ACCRETIVE
TO
BOTTOM LINE
Source text for Eikon: ID:nBSE99WbVs
Further company coverage: DLPA.NS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Dr. Lal PathLabs
See all newsBrief: Lal Pathlabs Says Unit Acquired Remaining 30% Equity Stake In Centrapath Labs Private Limited
India's Dr Lal PathLabs rises as Axis Securities initiates with 'buy'
India's Dr Lal PathLabs rises; analysts back SN Genelab deal
Brief: Lal Pathlabs Says Subsidiary Incorporated Dr Lal Pathlabs Indomed In Tashkent, Uzbekistan
India's Dr Lal PathLabs jumps to 4-year high after quarterly profit rise